Home/Pipeline/MTR-601

MTR-601

Cervical Dystonia

Phase 2Active

Key Facts

Indication

Cervical Dystonia

Phase

Phase 2

Status

Active

Company

Motric Bio

About Motric Bio

Motric Bio is a private, pre-revenue biotech company advancing a selective myosin-2 inhibitor platform for movement disorders. Its lead asset, MTR-601, has completed a Phase 1 safety study and is now in Phase 2 development for cervical dystonia. The company is an Aditum Bio portfolio company, founded following the in-licensing of its lead candidate, and is targeting a significant unmet need in neurological conditions characterized by chronic muscle overactivity.

View full company profile

Therapeutic Areas

Movement Disorders Neurology

Other Cervical Dystonia Drugs

Drug	Company	Phase	Status
DAXXIFY®	Revance	Phase 3	Active
ABP-450	AEON Biopharma	Phase 2	Active